Strategy: Why Big Pharmas Do What They Do — And How Silicon Valley Might Help Them Think Differently – Forbes

Good article on Frobes.com by David Shaywitz, MD. PhD (Harvard, MIT) on the challenges BioPharma companies are facing.  Of note, the "Three Alternative Approaches" does a great job summarizing the leading edge of new ways to address current challenges.  

Dr. Shaywitz’s  "Analytics" and "Phenotype" alternatives that are described highlight the potential value of the integration of disparate data sets and Patient Centric Analyses.  The alternatives may be particularly well suited for disease categories where the ideal patient population is small.   Today’s niche disease categories have created a need to identify small subsets of patients.  These are individual patients who are difficult to target within a larger disease with traditional data sets.  There are new patient centric analytic strategies and data sets available to meet this need.